問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Link to Hospital │ Link to Clinical Trial Center

  • 1,704

    Total Beds

  • 806

    Total Doctors

  • ctc@ms.kmuh.org.tw
  • Yu-Sam Lin
  • 886-7-3121101#6643
  • 807Kaohsiung CityKaohsiung SanminNo.100, Tzyou 1st Rd., Sanmin Dist.,Sanmin,Kaohsiung City 807

Recruiting Trial

596Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

1336Cases

2021-08-01 - 2023-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2019-01-01 - 2024-05-17

Phase III

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) plus Platinum and Fluoropyrimidine Versus Placebo plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

  • Condition/Disease

    Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

  • Test Drug

    Tislelizumab

Participate Sites
4Sites

Recruiting3Sites

王照元
Kaohsiung Municipal Gangshan Hospital

未分科

趙毅
Taipei Veterans General Hospital

2019-01-11 - 2024-12-31

Phase II

An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma

  • Condition/Disease

    Follicular Lymphoma (FL)

  • Test Drug

    Zanubrutinib (BGB-3111)

Participate Sites
7Sites

Recruiting2Sites

Terminated5Sites

2021-10-20 - 2023-11-02

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2010-06-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2019-12-01 - 2025-06-16

Phase III

Randomized, Open-label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M)

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    Venetoclax Venetoclax

Participate Sites
4Sites

Recruiting4Sites

2015-03-15 - 2017-05-30

Phase II

: A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 or Genotype 3 Infection (SURVEYOR-II)

  • Condition/Disease

    Chronic Hepatitis C Virus (HCV)

  • Test Drug

    ABT-530, ABT-493

Participate Sites
6Sites

Terminated5Sites

2015-10-26 - 2017-05-30

Phase III

A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 1 Infection (ENDURANCE-1)

  • Condition/Disease

    Chronic Hepatitis C Virus Genotype 1 Infection

  • Test Drug

    ABT-493/ABT-530

Participate Sites
9Sites

Terminated8Sites

彭成元
China Medical University Hospital-Taipei

未分科

朱啟仁
Taipei Veterans General Hospital

Digestive System Department

2015-09-16 - 2017-06-30

Phase III

An Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered with Ribavirin (RBV) in Treatment-Naïve and Treatment-Experienced Asian Adults with Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis

  • Condition/Disease

    Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis

  • Test Drug

    ABT-450/Ritonavir/ABT-267, ABT-333, Ribavirin

Participate Sites
6Sites

Terminated5Sites

朱啟仁
Taipei Veterans General Hospital

Digestive System Department

彭成元
China Medical University Hospital-Taipei

未分科

2015-10-20 - 2017-05-30

Phase III

A Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 2 Infection (ENDURANCE-2)

  • Condition/Disease

    Chronic Hepatitis C Virus Genotype 2 Infection

  • Test Drug

    ABT-493/ABT-530

Participate Sites
7Sites

Terminated4Sites

Study ended1Sites

彭成元
China Medical University Hospital

Digestive System Department

彭成元
China Medical University Hospital-Taipei

未分科

1 79 80 81 82 83 134
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB